EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells

Mohammad Mahbubul Hoque, Yuichi Iida, Hitoshi Kotani, Mamoru Harada iD

Cancer Reports · 2024

DOI: 10.1002/cnr2.2075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Mohammad Mahbubul Hoque und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Pancreatic Neoplasms, Cellular Senescence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST SPRING, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gemcitabine (GEM) is often used to treat pancreatic cancer. Many anti‐cancer drugs induce cancer cell death, but some cells survive after cell cycle arrest. Such a response to DNA damage is termed cellular senescence. Certain drugs, including the Bcl‐2‐family inhibitor ABT‐263, kill senescent cells; this is termed senolysis. In this study, we examined the therapeutic benefits of ABT‐263 in GEM‐induced senescence of human pancreatic cancer cells. Methods and Results Of four pancreatic cancer cell lines (PANC‐1, AsPC‐1, CFPAC‐1, and PANC10.05), GEM induced senescent features in PANC‐1 and AsPC‐1 cells, including increases in the cell sizes and expression levels of mRNAs encoding interleukin (IL)‐6/IL‐8 and induction of β‐galactosidase. Successive treatment with GEM and ABT‐263 triggered apoptosis in PANC‐1 and AsPC‐1 cells and suppressed colony formation significantly. Senolysis of GEM‐induced senescent pancreatic cancer cells by ABT‐263 was triggered by a Bcl‐xL inhibitor, but not by a Bcl‐2 inhibitor, suggesting a central role for Bcl‐xL in senolysis. In a xenograft mouse model, combined treatment with GEM and ABT‐737 (an ABT‐263 analog exhibiting the same specificity) suppressed in vivo growth of AsPC‐1 significantly.

Conclusion

Together, our results indicate that sequential treatment with GEM and senolytic drugs effectively kill human pancreatic cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineDeoxycytidinePancreatic NeoplasmsCellular SenescenceSulfonamidesAniline CompoundsXenograft Model Antitumor AssaysApoptosisHumansAnimalsMiceCell Line, TumorMice, NudeCell ProliferationSenotherapeutics

Stichwörter der Autor:innen

Bcl‐xLgemcitabinepancreatic cancersenescencesenolysis

Substanzen

GemcitabineDeoxycytidineSulfonamidesnavitoclaxAniline CompoundsSenotherapeutics

Autor:innen und Institutionen

  • Department of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.

ORCID-Profile: Mamoru Harada

Förderung

  • JST SPRING
  • JSPS KAKENHI

Zitieren

APA

Hoque, M. M., Iida, Y., Kotani, H., & Harada, M. (2024). Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells. Cancer Reports. https://doi.org/10.1002/cnr2.2075

Vancouver

Hoque MM, Iida Y, Kotani H, Harada M. Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells. Cancer Reports. 2024. doi:10.1002/cnr2.2075

BibTeX
@article{Hoque2024,
  author = {Hoque, Mohammad Mahbubul and Iida, Yuichi and Kotani, Hitoshi and Harada, Mamoru},
  title = {Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2075}
}
Kostenlos starten →